References
- Bryan LE. General mechanisms of resistance to antibi-otics. J Antimicrob Chemother 1988; 22 (suppl A): 1-15.
- Silver LL, Bostian KA. Discovery and development of new antibiotics: the problem of antibiotic resistance. Antimicrob Agents Chemother 1993; 37: 377–383.
- Gold HS, Moellering RC. Antimicrobial drug resis-tance. N Engl J Med 1996; 335: 1445–1453.
- Murray BE. Problems and mechanisms of antimicro-bial resistance. Infect Dis Clin N Am 1989; 3: 423–439.
- Livermore DM. Beta-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557–584.
- Mandell GL. In vitro microbiology and pharmacoki-netics of piperacillin. Clin Ther 1985; 7 (Suppl B): 28-35.
- Holmes B, Richards DM, Brogden RN, Heel RC. Piperacillin, a review of its antibacterial activity, pharmaco-kinetic properties and therapeutic use. Drugs 1984; 28: 375–425.
- Livermore DM. Evolution of beta-lactamase inhibitors. Intensive Care Med 1994; 20(Suppl 3): 10–13.
- Baron EJ, Jones RN. National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical cen-ters. Diagn Microbiol Infect Dis 1995; 21: 141–151.
- Chen HY, Bonfiglio G, Allen M, et al. Multicenter survey of the comparative in-vitro activity of piperacillin-tazobactam against bacteria from hospitalized patients in the British Isles. J Antimicrob Chemother 1993; 32: 247–266.
- Verbist L, Verhaegen J, Wouters Ch, Vandenhoven G and multicenter study group. Comparative activity of piperacillin-tazobactam against 5625 isolates from hospital-ized patients. J Antimicrob Chemother 1996; 37: 285–293.
- O'Brien TF, Acar JF, Medeiros AA, Norton RA, Goldstein F, Kent RL. International comparison of preva-lence of resistance to antibiotics. JAMA 1978; 239: 1518–1523.
- Akova M, Yang Y, Livermore DM. Interactions of tazobactam and davulanate with inducibly and constitutive-ly expressed Class I beta-lactamases. J Antimicrob Chemother 1990; 25: 199–208.
- Moellering RC Jr. Importance of beta-lactamase inhibitors in overcoming bacterial resistance. Infect Dis Clin Pract 1995; 4(Suppl 1): 1–8.
- Livermore DM. Determinants of the activity of beta-lactamase inhibitor combinations. J Antimicrob Chemother 1993; 31 (Suppl A): 9-21.
- The Greek Society for Microbiology. Antibiotic resis-tance among Gram negative bacilli in 19 Greek hospitals. J Hosp Infect 1989; 14: 177–181.
- Legakis NJ, Tzouvelekis LS, Tsakris A, Legakis JN, Vatopoulos AC. On the incidence of antibiotic resistance among aerobic Gram-negative rods isolated in Greek hospi-tals. J Hosp Infect 1993; 24: 233–237.